PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.28%
Net income growth of 10.28% while Biotechnology median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
720.76%
D&A growth of 720.76% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
100.00%
Deferred tax growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-18.24%
SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-114.66%
Working capital is shrinking yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-121.66%
AP shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
139.41%
Growth of 139.41% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-139.67%
Other non-cash items dropping yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-28.06%
Negative CFO growth while Biotechnology median is -3.46%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-383.87%
CapEx declines yoy while Biotechnology median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-383.87%
Reduced investing yoy while Biotechnology median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
-88.00%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.